Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells

I. Varga, K. Rácz, Róbert Kiss, László Füt/t:o, Miklós Tóth, Orlin Sergev, E. Gláz

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Etomidate has been shown to inhibit corticosteroid secretion in the normal adrenal gland, but its direct effect in human pathologic adrenals has not been clearly established. In the present study the effect of varying doses of etomidate (10-11 -10-5 M) was investigated on basal and adrenocorticotrophic hormone (ACTH)-stimulated corticosteroid secretions in isolated adrenocortical cells obtained from two patients with primary aldosteronism (adenoma and micronodular hyperplasia) and in those from a patient with Cushing's syndrome (adenoma). In cells from primary aldosteronism, increasing concentrations etomidate (10-11 -10-5 M) produced a dose-dependent decrease of basal and ACTH-stimulated cortisol, aldosterone, 18-hydroxycorticosterone, and corticosterone secretions (ED50: 10-8 M for each of these corticosteroids). In the same cells, the secretions of 11-deoxycortisol and deoxycorticosterone were increased in the presence of low (10-9 - 10-7 M) but not high doses of etomidate (10-6 -10-5 M). In cells from Cushing's syndrome the changes in costicosteroid secretion were similar to those found in primary aldosteronism except that aldosterone and 18-hydroxycorticosterone could not be determined due to their low levels. Thus the potent inhibition of corticosteroids in human pathologic adrenocortical cells in the presence of low concentrations of etomidate may be predominantly due to inhibition of the 11β-hydroxylase enzyme, whereas higher doses of the drug may inhibit earlier steps of the corticosteroid biosynthetic pathway. (Steroids 58:64-68, 1993).

Original languageEnglish
Pages (from-to)64-68
Number of pages5
JournalSteroids
Volume58
Issue number2
DOIs
Publication statusPublished - 1993

Fingerprint

Etomidate
Adrenal Cortex Hormones
Hyperaldosteronism
18-Hydroxycorticosterone
Cushing Syndrome
Aldosterone
Adenoma
Adrenocorticotropic Hormone
Cortodoxone
Desoxycorticosterone
Biosynthetic Pathways
Adrenal Glands
Corticosterone
Mixed Function Oxygenases
Hyperplasia
Hydrocortisone
Steroids
Enzymes
Pharmaceutical Preparations

Keywords

  • 11β-hydroxylase enzyme (human)
  • adrenocortical adenoma cells (human)
  • aldosterone inhibitor
  • corticosteroid biosynthesis (human)
  • corticosteroid inhibitor
  • cortisol inhibitor
  • etomidate
  • steroids

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Molecular Biology

Cite this

Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells. / Varga, I.; Rácz, K.; Kiss, Róbert; Füt/t:o, László; Tóth, Miklós; Sergev, Orlin; Gláz, E.

In: Steroids, Vol. 58, No. 2, 1993, p. 64-68.

Research output: Contribution to journalArticle

Varga, I. ; Rácz, K. ; Kiss, Róbert ; Füt/t:o, László ; Tóth, Miklós ; Sergev, Orlin ; Gláz, E. / Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells. In: Steroids. 1993 ; Vol. 58, No. 2. pp. 64-68.
@article{0bfbb4b3e60a4468bf140e3a798bf989,
title = "Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells",
abstract = "Etomidate has been shown to inhibit corticosteroid secretion in the normal adrenal gland, but its direct effect in human pathologic adrenals has not been clearly established. In the present study the effect of varying doses of etomidate (10-11 -10-5 M) was investigated on basal and adrenocorticotrophic hormone (ACTH)-stimulated corticosteroid secretions in isolated adrenocortical cells obtained from two patients with primary aldosteronism (adenoma and micronodular hyperplasia) and in those from a patient with Cushing's syndrome (adenoma). In cells from primary aldosteronism, increasing concentrations etomidate (10-11 -10-5 M) produced a dose-dependent decrease of basal and ACTH-stimulated cortisol, aldosterone, 18-hydroxycorticosterone, and corticosterone secretions (ED50: 10-8 M for each of these corticosteroids). In the same cells, the secretions of 11-deoxycortisol and deoxycorticosterone were increased in the presence of low (10-9 - 10-7 M) but not high doses of etomidate (10-6 -10-5 M). In cells from Cushing's syndrome the changes in costicosteroid secretion were similar to those found in primary aldosteronism except that aldosterone and 18-hydroxycorticosterone could not be determined due to their low levels. Thus the potent inhibition of corticosteroids in human pathologic adrenocortical cells in the presence of low concentrations of etomidate may be predominantly due to inhibition of the 11β-hydroxylase enzyme, whereas higher doses of the drug may inhibit earlier steps of the corticosteroid biosynthetic pathway. (Steroids 58:64-68, 1993).",
keywords = "11β-hydroxylase enzyme (human), adrenocortical adenoma cells (human), aldosterone inhibitor, corticosteroid biosynthesis (human), corticosteroid inhibitor, cortisol inhibitor, etomidate, steroids",
author = "I. Varga and K. R{\'a}cz and R{\'o}bert Kiss and L{\'a}szl{\'o} F{\"u}t/t:o and Mikl{\'o}s T{\'o}th and Orlin Sergev and E. Gl{\'a}z",
year = "1993",
doi = "10.1016/0039-128X(93)90054-Q",
language = "English",
volume = "58",
pages = "64--68",
journal = "Steroids",
issn = "0039-128X",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells

AU - Varga, I.

AU - Rácz, K.

AU - Kiss, Róbert

AU - Füt/t:o, László

AU - Tóth, Miklós

AU - Sergev, Orlin

AU - Gláz, E.

PY - 1993

Y1 - 1993

N2 - Etomidate has been shown to inhibit corticosteroid secretion in the normal adrenal gland, but its direct effect in human pathologic adrenals has not been clearly established. In the present study the effect of varying doses of etomidate (10-11 -10-5 M) was investigated on basal and adrenocorticotrophic hormone (ACTH)-stimulated corticosteroid secretions in isolated adrenocortical cells obtained from two patients with primary aldosteronism (adenoma and micronodular hyperplasia) and in those from a patient with Cushing's syndrome (adenoma). In cells from primary aldosteronism, increasing concentrations etomidate (10-11 -10-5 M) produced a dose-dependent decrease of basal and ACTH-stimulated cortisol, aldosterone, 18-hydroxycorticosterone, and corticosterone secretions (ED50: 10-8 M for each of these corticosteroids). In the same cells, the secretions of 11-deoxycortisol and deoxycorticosterone were increased in the presence of low (10-9 - 10-7 M) but not high doses of etomidate (10-6 -10-5 M). In cells from Cushing's syndrome the changes in costicosteroid secretion were similar to those found in primary aldosteronism except that aldosterone and 18-hydroxycorticosterone could not be determined due to their low levels. Thus the potent inhibition of corticosteroids in human pathologic adrenocortical cells in the presence of low concentrations of etomidate may be predominantly due to inhibition of the 11β-hydroxylase enzyme, whereas higher doses of the drug may inhibit earlier steps of the corticosteroid biosynthetic pathway. (Steroids 58:64-68, 1993).

AB - Etomidate has been shown to inhibit corticosteroid secretion in the normal adrenal gland, but its direct effect in human pathologic adrenals has not been clearly established. In the present study the effect of varying doses of etomidate (10-11 -10-5 M) was investigated on basal and adrenocorticotrophic hormone (ACTH)-stimulated corticosteroid secretions in isolated adrenocortical cells obtained from two patients with primary aldosteronism (adenoma and micronodular hyperplasia) and in those from a patient with Cushing's syndrome (adenoma). In cells from primary aldosteronism, increasing concentrations etomidate (10-11 -10-5 M) produced a dose-dependent decrease of basal and ACTH-stimulated cortisol, aldosterone, 18-hydroxycorticosterone, and corticosterone secretions (ED50: 10-8 M for each of these corticosteroids). In the same cells, the secretions of 11-deoxycortisol and deoxycorticosterone were increased in the presence of low (10-9 - 10-7 M) but not high doses of etomidate (10-6 -10-5 M). In cells from Cushing's syndrome the changes in costicosteroid secretion were similar to those found in primary aldosteronism except that aldosterone and 18-hydroxycorticosterone could not be determined due to their low levels. Thus the potent inhibition of corticosteroids in human pathologic adrenocortical cells in the presence of low concentrations of etomidate may be predominantly due to inhibition of the 11β-hydroxylase enzyme, whereas higher doses of the drug may inhibit earlier steps of the corticosteroid biosynthetic pathway. (Steroids 58:64-68, 1993).

KW - 11β-hydroxylase enzyme (human)

KW - adrenocortical adenoma cells (human)

KW - aldosterone inhibitor

KW - corticosteroid biosynthesis (human)

KW - corticosteroid inhibitor

KW - cortisol inhibitor

KW - etomidate

KW - steroids

UR - http://www.scopus.com/inward/record.url?scp=0027512384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027512384&partnerID=8YFLogxK

U2 - 10.1016/0039-128X(93)90054-Q

DO - 10.1016/0039-128X(93)90054-Q

M3 - Article

C2 - 8387232

AN - SCOPUS:0027512384

VL - 58

SP - 64

EP - 68

JO - Steroids

JF - Steroids

SN - 0039-128X

IS - 2

ER -